Back to list
RETISOM, a pioneering project!
June 14, 2024

🌟 Exciting Milestone at BCN Peptides! 🌟

🚀 BCN Peptides has recently launched the RETISOM Clinical Trial, aimed at patients with moderate-severe Diabetic Retinopathy. The study has been activated across 8 renowned opthalmological centers: ICR, VHIR, IOA, St Pau, IMO, IOFV, C. Baviera and IOBA

👁️ Study Objective: To evaluate the efficacy of a non-invasie solution based on eyedrops, to control disease progression before serious complications such as edema, neovascularization, and retinal hemorrhage occur.


💡 Interested in more details or participating? Visit our study site (REec Identifier: 2023-505791-30-01) or contact our team at ctinfodesk@bcnpeptides.com


🤝 Collaborations and progress are key to addressing challenges in eye care. Join us on this journey towards innovation!

#RETISOM #DiabticRetinopathy #Innovation #Eyecare #Vision #Advancedtherapies